WHO Trial Finds Remdesivir Has 'No Meaningful Effect' In COVID-19 Patients
Published
The medicine is one of the few to win regulatory approval as a treatment for the disease, but has fallen out of favor with the health authority.
Full ArticlePublished
The medicine is one of the few to win regulatory approval as a treatment for the disease, but has fallen out of favor with the health authority.
Full ArticleKey drug candidate lenzilumab is a recombinant monoclonal antibody Designed to reduce sometimes dangerous side effects associated..
• The company's key drug candidate is lenzilumab, a recombinant monoclonal antibody • Conducting a Phase 3 clinical trial for..
Humanigen Inc (NASDAQ:HGEN) (FRA:0KB2) announced Friday positive interim Phase 3 data on lenzilumab to treat patients hospitalized..